Search Results for: FDA Accepts Larotrectinib NDA Grants
Articles
June 6, 2018
FDA Accepts Larotrectinib NDA & Grants Priority Review June 6, 2018
Loxo Oncology, Inc. recently announced the US FDA has accepted the company’s New Drug Application (NDA) and granted Priority Review for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion
